OVID — Ovid Therapeutics Inc

Ovid Therapeutics Inc (OVID) is a biotechnology company listed on NASDAQ. It is led by Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D., based in 441 Ninth Avenue, New York, NY, United States, 10001, with about 23 employees. Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Latest reported OVID revenue for 2025-09-30 was $132.0K. Net income was -$12.2M. Revenue was down 97.9% from 2025-06-30 to 2025-09-30. OVID currently screens at market cap $23.5M.

Use this OVID page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OVID quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OVID SEC filings page. Lician reads the product cache first so this HTML stays unique to Ovid Therapeutics Inc even when a live quote feed is slow.